Get started
Author

Alessandro Sanna

Observed names: A. Sanna, Sanna Alessandro
ORCID: 0000-0002-5015-381X
Observed ORCID: 0000-0002-5015-381X
OpenAlex ID: A5021290460
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
2025 · Jeff P. Sharman, Talha Munir, et al. · Journal of Clinical Oncology · 48
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
2025 · Angela Consagra, Luca Lanino, et al. · HemaSphere · 14
PDF
PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes
2023 · Enrico Attardi, Immacolata Andolfo, et al. · American Journal of Hematology · 8
PDF
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study
2025 · Ernesto Vigna, Enrica Antonia Martino, et al. · Hematological Oncology · 5
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort
2026 · Enrica Antonia Martino, Annalisa Pitino, et al. · Blood Advances · 4
PDF
Continuous venetoclax in treatment‐naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study
2023 · Andrea Visentin, Francesca Romana Mauro, et al. · American Journal of Hematology · 4
PDF
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort
2025 · Andrea Serafin, Alessandro Cellini, et al. · Blood Advances · 3
PDF
Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience
2025 · Idanna Innocenti, Annamaria Tomasso, et al. · Hematological Oncology · 3
PDF
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study
2024 · Francesco Autore, Andrea Visentin, et al. · American Journal of Hematology · 3
PDF
Incidence of severe COVID ‐19 in patients with chronic lymphocytic leukaemia or indolent B‐cell non‐Hodgkin lymphoma who received vaccination and pre‐exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi
2026 · Gian Matteo Rigolin, Stefano Soddu, et al. · British Journal of Haematology · 1
Long‐Term Clinical Outcomes, Adherence, Persistence, and Adverse Event Management in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
2026 · Santoleri Fiorenzo, Pennese Elsa, et al. · European Journal Of Haematology
PDF
POSTER: MDS-1103: Elevated Interleukin 1βand Reduced Interleukin 5 in Low-Risk Myelodysplastic Syndromes With Grade 2 or Higher Bone Marrow Fibrosis
2026 · Maria Stella Martino, Giorgio Mattiuz, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-951: Peripheral Blood Inflammatory Markers as Prognostic Indicators in Chronic Lymphocytic Leukemia
2026 · Chiara Maria Rapolla, Gabriella Carlomagno, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-951: Peripheral Blood Inflammatory Markers as Prognostic Indicators in Chronic Lymphocytic Leukemia
2026 · Chiara Maria Rapolla, Gabriella Carlomagno, et al. · Clinical Lymphoma Myeloma & Leukemia
MDS-1103: Elevated Interleukin 1βand Reduced Interleukin 5 in Low-Risk Myelodysplastic Syndromes With Grade 2 or Higher Bone Marrow Fibrosis
2026 · Maria Stella Martino, Giorgio Mattiuz, et al. · Clinical Lymphoma Myeloma & Leukemia
Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia
2026 · Francesca Morelli, Silvia Linari, et al. · Annals of Hematology
PDF
Leukemia cutis as a transient alarm bell of disease progression in a patient with chronic lymphocytic leukemia under watchful waiting
2026 · Simone Landini, Alberto Corrà, et al. · Mediterranean Journal of Hematology and Infectious Diseases
PDF
A landscape of genetic heterogeneity in germline predisposition to familial chronic lymphocytic leukemia
2025 · Luca Laurenti, Eugenio Sangiorgi, et al. · Research Square
PDF
POSTER: MDS-560 Real-World Outcomes and Predictors of Response and Progression in Lower-Risk Myelodysplastic Syndrome Patients Treated With Luspatercept: A Single-Center Experience
2025 · Angela Consagra, Luca Rigodanza, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CLL-1169 Autoimmune Manifestations in Patients With Chronic Lymphocytic Leukemia: A Retrospective Single-Center Study
2025 · Gabriella Carlomagno, Chiara Maria Rapolla, et al. · Clinical Lymphoma Myeloma & Leukemia
CLL-1169: Autoimmune Manifestations in Patients With Chronic Lymphocytic Leukemia: A Retrospective Single-Center Study
2025 · Gabriella Carlomagno, Chiara Maria Rapolla, et al. · Clinical Lymphoma Myeloma & Leukemia
MDS-560: Real-World Outcomes and Predictors of Response and Progression in Lower-Risk Myelodysplastic Syndrome Patients Treated With Luspatercept: A Single-Center Experience
2025 · Angela Consagra, Luca Rigodanza, et al. · Clinical Lymphoma Myeloma & Leukemia
Author response for "Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience"
2024 · Idanna Innocenti, Annamaria Tomasso, et al.
Comparison of Familial Versus Sporadic Forms of Chronic Lymphocytic Leukemia: An Italian Multicenter Case-Control Study
2024 · Alberto Fresa, Idanna Innocenti, et al. · Blood
PDF
Acalabrutinib in High-Risk Chronic Lymphocytic Leukemia Patients Naïve or Previous Treated. a Multicenter Retrospective Observational Real-Life Experience
2024 · Idanna Innocenti, Annamaria Tomasso, et al. · Blood
PDF
Works count: 29
Citation count: 93
H-index: 4
I10-index: 2
Year
Topic
Type